INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,105,682 | +60.6% | 4,212,820 | -4.2% | 0.00% | +100.0% |
| Q2 2023 | $48,630,487 | +18.4% | 4,396,970 | +43.7% | 0.00% | 0.0% |
| Q1 2023 | $41,081,619 | +7.7% | 3,058,944 | -0.8% | 0.00% | 0.0% |
| Q4 2022 | $38,159,385 | -6.8% | 3,084,833 | +5.1% | 0.00% | 0.0% |
| Q3 2022 | $40,960,000 | +9.1% | 2,936,187 | +8.0% | 0.00% | 0.0% |
| Q2 2022 | $37,541,000 | -13.1% | 2,718,354 | +2.4% | 0.00% | 0.0% |
| Q1 2022 | $43,201,000 | +18.8% | 2,655,257 | +19.0% | 0.00% | 0.0% |
| Q4 2021 | $36,360,000 | +3.6% | 2,232,092 | -5.6% | 0.00% | 0.0% |
| Q3 2021 | $35,100,000 | -25.0% | 2,363,463 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $46,811,000 | -17.8% | 2,344,158 | -5.0% | 0.00% | -50.0% |
| Q1 2021 | $56,926,000 | -7.8% | 2,466,443 | -1.3% | 0.00% | 0.0% |
| Q4 2020 | $61,711,000 | -31.7% | 2,498,408 | +14.6% | 0.00% | -33.3% |
| Q3 2020 | $90,369,000 | -20.9% | 2,179,635 | -8.6% | 0.00% | -40.0% |
| Q2 2020 | $114,267,000 | -18.5% | 2,385,046 | +7.1% | 0.01% | -28.6% |
| Q1 2020 | $140,149,000 | -51.1% | 2,225,984 | -3.8% | 0.01% | -36.4% |
| Q4 2019 | $286,809,000 | +85.6% | 2,314,468 | -0.6% | 0.01% | +83.3% |
| Q3 2019 | $154,511,000 | -11.0% | 2,328,385 | +6.7% | 0.01% | -14.3% |
| Q2 2019 | $173,650,000 | -20.6% | 2,182,374 | +11.6% | 0.01% | -30.0% |
| Q1 2019 | $218,672,000 | +6.8% | 1,954,871 | -3.8% | 0.01% | 0.0% |
| Q4 2018 | $204,833,000 | -23.2% | 2,032,287 | -3.7% | 0.01% | -16.7% |
| Q3 2018 | $266,700,000 | +56.4% | 2,110,651 | +3.8% | 0.01% | +50.0% |
| Q2 2018 | $170,553,000 | +117.1% | 2,032,593 | +59.1% | 0.01% | +100.0% |
| Q1 2018 | $78,573,000 | +12.6% | 1,277,197 | +7.0% | 0.00% | +33.3% |
| Q4 2017 | $69,751,000 | +3.5% | 1,193,962 | +2.9% | 0.00% | 0.0% |
| Q3 2017 | $67,371,000 | -51.0% | 1,160,750 | +2.2% | 0.00% | -57.1% |
| Q2 2017 | $137,538,000 | +13.7% | 1,136,015 | +6.2% | 0.01% | 0.0% |
| Q1 2017 | $120,944,000 | +37344.0% | 1,069,357 | +35917.4% | 0.01% | – |
| Q4 2016 | $323,000 | -39.5% | 2,969 | -8.6% | 0.00% | -100.0% |
| Q3 2016 | $534,000 | +73.9% | 3,249 | +51.6% | 0.00% | – |
| Q2 2016 | $307,000 | +24.8% | 2,143 | +11.9% | 0.00% | – |
| Q1 2016 | $246,000 | +246.5% | 1,915 | +301.5% | 0.00% | – |
| Q4 2015 | $71,000 | -2.7% | 477 | +7.7% | 0.00% | – |
| Q3 2015 | $73,000 | -31.8% | 443 | +0.2% | 0.00% | – |
| Q2 2015 | $107,000 | +0.9% | 442 | +17.9% | 0.00% | – |
| Q1 2015 | $106,000 | +86.0% | 375 | +3.0% | 0.00% | – |
| Q4 2014 | $57,000 | -33.7% | 364 | 0.0% | 0.00% | – |
| Q3 2014 | $86,000 | 0.0% | 364 | 0.0% | 0.00% | – |
| Q2 2014 | $86,000 | -90.4% | 364 | -86.7% | 0.00% | -100.0% |
| Q1 2014 | $899,000 | +8072.7% | 2,727 | +1532.9% | 0.00% | – |
| Q4 2013 | $11,000 | -8.3% | 167 | 0.0% | 0.00% | – |
| Q3 2013 | $12,000 | +71.4% | 167 | 0.0% | 0.00% | – |
| Q2 2013 | $7,000 | – | 167 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |